G
Gideon Koren
Researcher at Ariel University
Publications - 2007
Citations - 88165
Gideon Koren is an academic researcher from Ariel University. The author has contributed to research in topics: Pregnancy & Population. The author has an hindex of 129, co-authored 1994 publications receiving 81718 citations. Previous affiliations of Gideon Koren include McGill University Health Centre & University of Western Ontario.
Papers
More filters
Journal ArticleDOI
A multicenter, prospective study of fetal outcome following accidental carbon monoxide poisoning in pregnancy.
Gideon Koren,Teresa Sharav,Anne Pastuszak,Lorne K. Garrettson,Kelly Hill,Ivan Samson,Mark Rorem,Arlene King,Jill E. Dolgin +8 more
TL;DR: It is concluded that while severe CO poisoning poses serious short- and long-term fetal risk, mild accidental exposure is likely to result in normal fetal outcome and hyperbaric oxygen may decrease fetal hypoxia and improve outcome.
Journal ArticleDOI
Maternal-fetal transport of hypoglycaemic drugs.
TL;DR: The pharmacokinetic data available for hypoglycaemic drugs during pregnancy, as well as the potential role for the in vitro placenta perfusion model in the preclinical evaluation of drugs with potential usefulness in pregnancy are summarized.
Journal Article
Risks of untreated depression during pregnancy.
TL;DR: A growing body of literature investigating the effects of not treating depression on mother and developing fetus suggests that untreated depression is associated with adverse fetal outcomes and a higher risk of maternal morbidity, including suicide ideation and attempts, and postpartum depression.
Journal ArticleDOI
Determinants of recall and recall bias in studying drug and chemical exposure in pregnancy.
TL;DR: There was a recall bias in reporting alcohol consumption; postnatally, women with adverse outcome tended to report significantly less than the amount initially reported by them.
Journal ArticleDOI
Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study
TL;DR: Investigation of the fetal safety of exposure to natalizumab during the first trimester of pregnancy using disease-matched (DM) and healthy control (HC) comparison groups found no significant difference between the Exposed and DM groups.